Information Provided By:
Fly News Breaks for October 17, 2018
ARWR
Oct 17, 2018 | 05:27 EDT
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Arrowhead Pharmaceuticals with a $25 price target following yesterday's R&D day. The analyst is a buyer on recent weakness with the stock down 25% since announcing the Janssen deal earlier this month. Arrowhead now trades at a market capitalization of $1.27B with pro forma cash of $328M to advance its wholly-owned RNAi pipeline, Tenthoff tells investors in a research note. He points out the company will give an oral presentation on ARO-AAT including Phase I safety and serum Alpha-1 Antitrypsin levels in healthy volunteers in a late-breaker at the annual American Association for the study of Liver Diseases meeting on November 12.
News For ARWR From the Last 2 Days
There are no results for your query ARWR